Envestnet Asset Management
DYN icon

Envestnet Asset Management’s Dyne Therapeutics DYN Stock Holding History

Envestnet Asset Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.48M Sell
66,583
-1,810
-3% -$33.7K ﹤0.01% 3372
2026
Q1 		$1.24M Buy
+68,393
New +$1.18M ﹤0.01% 3338

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Envestnet Asset Management's DYN Position: Q2 2026 in Review

Envestnet Asset Management reduced its Dyne Therapeutics (DYN) stake by 2.6% in Q2 2026, selling an estimated $33.7K and leaving 66,583 shares worth $1.48M. The position accounts for ﹤0.01% of the portfolio, ranked #3372.

Envestnet Asset Management first reported a position in DYN in Q1 2026 and has held it in 2 quarters since. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Envestnet Asset Management held 66,583 shares of Dyne Therapeutics worth $1.48M as of Q2 2026.
  • Envestnet Asset Management sold 1,810 Dyne Therapeutics shares in Q2 2026, an estimated $33.7K.
  • Dyne Therapeutics made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #3372 holding.
  • Envestnet Asset Management first reported a position in Dyne Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.